A renewable tissue resource of phenotypically stable, biologically and ethnically diverse, patient-derived human breast cancer xenograft models
about
Development and Characterization of Bladder Cancer Patient-Derived Xenografts for Molecularly Guided Targeted TherapyMTDH-SND1 interaction is crucial for expansion and activity of tumor-initiating cells in diverse oncogene- and carcinogen-induced mammary tumorsEndocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenograftsPatient-derived xenograft models of colorectal cancer in pre-clinical research: a systematic reviewBioengineering Models for Breast Cancer ResearchAn Integrative Approach to Precision Cancer Medicine Using Patient-Derived XenograftsPatient-derived xenograft models of breast cancer and their predictive powerPreclinical mouse cancer models: a maze of opportunities and challenges.Patient-derived xenografts: a relevant preclinical model for drug developmentPatient-derived tumour xenografts for breast cancer drug discoveryPrioritizing therapeutic targets using patient-derived xenograft modelsUsing heterogeneity of the patient-derived xenograft model to identify the chemoresistant population in ovarian cancerAdvances in tumor screening, imaging, and avatar technologies for high-grade serous ovarian cancer.Modeling of nanotherapeutics delivery based on tumor perfusion.Wnt-responsive cancer stem cells are located close to distorted blood vessels and not in hypoxic regions in a p53-null mouse model of human breast cancer.Scaffold-integrated microchips for end-to-end in vitro tumor cell attachment and xenograft formationA class of extracellular vesicles from breast cancer cells activates VEGF receptors and tumour angiogenesis.Decoding breast cancer tissue-stroma interactions using species-specific sequencingPatient-derived xenograft platform of OSCC: a renewable human bio-bank for preclinical cancer research and a new co-clinical model for treatment optimization.Pre-clinical validation of a selective anti-cancer stem cell therapy for Numb-deficient human breast cancers.Resistance to Taxanes in Triple-Negative Breast Cancer Associates with the Dynamics of a CD49f+ Tumor-Initiating Population.Patient-derived xenografts of triple-negative breast cancer reproduce molecular features of patient tumors and respond to mTOR inhibition.Immunocompetent mouse allograft models for development of therapies to target breast cancer metastasis.Stability of preclinical models of aggressive renal cell carcinomas.Patient-derived xenograft models: an emerging platform for translational cancer researchDrug-repositioning screening identified piperlongumine as a direct STAT3 inhibitor with potent activity against breast cancer.Higher susceptibility of NOD/LtSz-scid Il2rg (-/-) NSG mice to xenotransplanted lung cancer cell linesCirculating and disseminated tumor cells from breast cancer patient-derived xenograft-bearing mice as a novel model to study metastasis.Setting up a wide panel of patient-derived tumor xenografts of non-small cell lung cancer by improving the preanalytical steps.Identification and Characterization of Separase Inhibitors (Sepins) for Cancer Therapy.Spontaneous Post-Transplant Disorders in NOD.Cg- Prkdcscid Il2rgtm1Sug/JicTac (NOG) Mice Engrafted with Patient-Derived Metastatic Melanomas.Ability to Generate Patient-Derived Breast Cancer Xenografts Is Enhanced in Chemoresistant Disease and Predicts Poor Patient Outcomes.Wild-Type N-Ras, Overexpressed in Basal-like Breast Cancer, Promotes Tumor Formation by Inducing IL-8 Secretion via JAK2 Activation.NSG Mice Provide a Better Spontaneous Model of Breast Cancer Metastasis than Athymic (Nude) Mice.Network-based approach to identify prognostic biomarkers for estrogen receptor-positive breast cancer treatment with tamoxifenLow Dose, Low Cost Estradiol Pellets Can Support MCF-7 Tumour Growth in Nude Mice without Bladder Symptoms.Epithelial derived CTGF promotes breast tumor progression via inducing EMT and collagen I fibers deposition.Antitumor activity of Cetuximab in combination with Ixabepilone on triple negative breast cancer stem cellsp53 deficiency linked to B cell translocation gene 2 (BTG2) loss enhances metastatic potential by promoting tumor growth in primary and metastatic sites in patient-derived xenograft (PDX) models of triple-negative breast cancer.Integrated Bottom-Up and Top-Down Proteomics of Patient-Derived Breast Tumor Xenografts.
P2860
Q21131727-9502F60C-C1E0-45F1-AD31-E83C2DD93EA3Q24300043-2C04D0BC-B413-428C-A541-9A4B2849235FQ24621116-75F5AE3B-00FE-48E3-B094-409FF2142692Q26741651-E55E661E-D925-4326-A90B-117D0E587583Q26770495-6DC88B35-9C45-4FD3-B5FE-4AA6A689B88BQ26772895-B52DF0E8-A8DC-4E3B-AA25-EF2FEB138217Q27026531-A09A8FC4-F610-48A7-9BF2-237CF9F07878Q27322080-1D66C61B-9EED-458F-B9B3-1C58C8DA09EAQ28067191-E6C8687F-5854-435E-8289-75D84092F680Q28080046-F8F78CEE-3399-4516-B4B9-EE7A08DC3338Q28083993-A6DE150F-4851-4D27-8B1A-33313AEB1685Q30409503-78BEA5CD-AE8D-483D-ADF0-D184154C2FEFQ30423597-34563286-5E6A-4CD6-8B96-F5DA88ED358CQ30544603-9FDDBE9D-29E4-4452-BA32-BFDE6DDA3499Q30581875-3F63CEE9-7703-48D7-BF31-7EF84250B29DQ30691831-9E60C30A-4BDB-4DE3-8AFD-C51851E70178Q30839218-345CB147-F768-4E6A-8872-BA692E65CA9FQ30986777-9752B4AC-C50C-48ED-900E-E37245BFC2A1Q33457995-0E1A971B-8232-4F3E-AFCD-CE5AD5A734A5Q33626025-4FE9A2B4-C8D2-4ABF-8B9F-1483C8F7B8E7Q33659361-5A6555F3-D3DD-4092-9B3A-A8B023E8FD91Q33739184-61AD97D4-9DF4-419F-B880-A990BF5804FBQ33761491-C08B1D01-1DB0-4DCE-9B58-012D1B721666Q33898564-076B67E4-9739-47DB-9C18-2A76DD6911ACQ34205518-C46E0C11-CBFB-4773-BF58-A476EE12024FQ34276296-DFCC88F8-7996-4DD0-AABE-540EAD8A1D40Q34415301-0CD94578-00DB-4FFF-BFAA-63033C8AFB0AQ35053624-4598E3F4-B932-40DC-80F0-824005AA8FA0Q35084915-1892C92B-5681-41DC-9854-9FFA166AA062Q35094092-23CF0A1E-E15E-4775-981E-AB567ECF28A1Q35634016-F66EBF9C-3EB5-4C94-B122-148B6459ED1DQ35760892-ED04D5B2-59A6-42A4-A56E-74A7C0516DCCQ35883071-AFEC456B-0A76-45B1-8CBC-4A1A95A435A0Q36143238-7283FF41-6764-480A-A4D1-8D1F5EF97D79Q36214336-58A4B55F-9B52-4384-942C-E7742F82ABF8Q36275032-8C4930DD-D568-4F95-97A1-8BAFFDF2C7D2Q36413175-0C55C0D2-F94B-4C2B-9D69-D7BDD9242E6CQ36457669-204B11A2-2630-44B7-A0A7-F96A2120BEE9Q36507886-A8ACDE21-C616-48AF-99A4-DF4BDD729A81Q36604140-4D11DFD4-5081-4857-AB3E-3F2BA8D1E13F
P2860
A renewable tissue resource of phenotypically stable, biologically and ethnically diverse, patient-derived human breast cancer xenograft models
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 04 June 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
A renewable tissue resource of ...... breast cancer xenograft models
@en
A renewable tissue resource of ...... reast cancer xenograft models.
@nl
type
label
A renewable tissue resource of ...... breast cancer xenograft models
@en
A renewable tissue resource of ...... reast cancer xenograft models.
@nl
prefLabel
A renewable tissue resource of ...... breast cancer xenograft models
@en
A renewable tissue resource of ...... reast cancer xenograft models.
@nl
P2093
P2860
P1433
P1476
A renewable tissue resource of ...... breast cancer xenograft models
@en
P2093
Aleix Prat
Alejandro Contreras
Amber M Froehlich
Anne C Pavlick
Carolina Gutierrez
Chad A Shaw
Edward S Chen
Gordon B Mills
Helen Wong
Ivana Petrovic
P2860
P304
P356
10.1158/0008-5472.CAN-12-4081
P407
P577
2013-06-04T00:00:00Z